Pharmaceutical Preparation and Pipeline
Avicanna’s first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America
Pipeline of proprietary drug candidates
Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of indication specific drug candidates that are in various stages of clinical development, registration, and commercialization
These cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
Trunerox™ – 10% CBD (100 mg/ml Cannabidiol)
Pharmaceutical preparation under GMP standards with completed technical dossier. Expected marketing authorization during 2023 in Colombia, Ecuador, and Brazil
Utilizing Avicanna’s proprietary formulations and vertical integration to deliver a pharmaceutical CBD preparation with affordable pricing into the Latin American Markets.